Pencis
Scopus
Orcid
Dr. Rong Stephanie Huang's academic journey began with her pursuit of pharmacology at the University of Minnesota, where she eventually earned the title of Distinguished McKnight University Professor. Her early academic pursuits laid the foundation for her distinguished career in the field.
Throughout her career, Dr. Huang has held prestigious academic appointments, including her current position in the Department of Experimental and Clinical Pharmacology at the University of Minnesota. Her commitment to advancing pharmacology is evident in her leadership roles and contributions to various professional societies.
Dr. Huang's research primarily focuses on personalized and precision medicine, particularly in oncology. Her work aims to tailor treatments to individual patients by understanding the genetic and molecular mechanisms underlying cancer progression. This research has significant implications for improving patient outcomes in cancer treatment.
As a respected leader in pharmacology, Dr. Huang's influence extends beyond her research. Her leadership roles in organizations such as the International Pharmaceutical Federation (FIP) highlight her dedication to advancing the field on a global scale. Her contributions have shaped the landscape of personalized medicine and oncology research.
Dr. Huang's research has garnered substantial attention within the academic community, evidenced by the numerous citations her work has received. Her findings have contributed to advancing knowledge in pharmacology, particularly in the realm of personalized medicine and cancer research.
Dr. Huang's legacy is characterized by her significant contributions to pharmacology and personalized medicine. Her ongoing leadership roles and mentorship efforts ensure that her impact will endure for future generations of pharmacologists. As she continues her research and advocacy, Dr. Huang will undoubtedly leave a lasting legacy in the field.
Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis.
Integration of Computational Pipeline to Streamline Efficacious Drug Nomination and Biomarker Discovery in Glioblastoma.
Integration of pan-cancer cell line and single-cell transcriptomic profiles enables inference of therapeutic vulnerabilities in heterogeneous tumors.
A review of computational methods for predicting cancer drug response at the single-cell level through integration with bulk RNAseq data.